drugset
drugset / Trial / NCT00326664

AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors

NCT00326664 ↗

Phase 1 Completed 55 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial is studying the side effects and best dose of AZD2171 in treating young patients with recurrent, progressive, or refractory primary CNS tumors. AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Timeline

Start
2006-03
Primary completion
2015-07
Completion
2015-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Cediranib Small molecule — Oral

Indications

atypical teratoid rhabdoid tumor cerebellar astrocytoma childhood brain meningioma childhood brain stem glioma childhood central nervous system germ cell tumor childhood central nervous system primitive neuroectodermal neoplasm childhood cerebral astrocytoma childhood medulloblastoma childhood oligodendroglioma childhood spinal cord tumor grade II meningioma grade III meningioma optic pathway glioma pediatric infratentorial ependymoma pediatric supratentorial ependymoma pineoblastoma subependymal giant cell astrocytoma